Interferon alfa-2b: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Interferon alfa-2b}} | {{Interferon alfa-2b}} | ||
'''''For patient information, click <u>[[XXXXX (patient information)|here]]'''''</u>. | |||
{{CMG}} | {{CMG}} | ||
Revision as of 18:19, 8 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Interferon alfa-2b is an antiviral drug discovered and marketed by Schering-Plough under the tradename Intron-
®. It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.
Category
Antiviral
US Brand Names
INTRON A®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages